GEN Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
EN
13/10/2020

Underlying

GENGenmab A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genmab A/S

 PRESS RELEASE
Free
GEN GENMAB A/S

Correction to Company Announcement No. 13 of March 2, 2026

Correction to Company Announcement No. 13 of March 2, 2026 Company Announcement COPENHAGEN, Denmark; March 2, 2026 – (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that the share price associated with these transactions was DKK 0,00. The correct price is DKK 1,867.50. In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the tr...

March 2, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; March 2, 2026 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The Company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to p...

March 2, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than March 31, 2026. The following transactions were executed under the program from February 23 to February 27, 2026:  No. of sharesAverage price (DKK...

March 2, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Transactions with shares and linked securities in Genmab A/S made by m...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 27, 2026 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...

February 27, 2026 1 EN
 PRESS RELEASE
Free
GEN GENMAB A/S

Grant of Restricted Stock Units to Management and Employees and Grant ...

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; February 27, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 455,004 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK...

February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch